Baystreet.ca - Vertex Leaps on Purchasing Kidney Research Firm
Vertex Pharmaceuticals (NASDAQ:VRTX) will buy Alpine Immune Sciences (NASDAQ:ALPN) for about $4.9 billion in cash, gaining access to the biotech firm’s treatment for an autoimmune disease of the kidney. The deal values each share of Alpine at $65, ...